Evidence map›Paper›PMID 35046019›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2022

Tuning protein half-life in mouse using sequence-defined biopolymers functionalized with lipids.

Koen Vanderschuren, Pol Arranz-Gibert, Minsoo Khang, Dagan Hadar, Alice Gaudin, Fan Yang, Ewa Folta-Stogniew, W Mark Saltzman, Miriam Amiram, Farren J Isaacs

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Koen VanderschurenDepartment of Molecular, Cellular & Developmental Biology, Yale University, New Haven, CT 06520.
Pol Arranz-GibertDepartment of Molecular, Cellular & Developmental Biology, Yale University, New Haven, CT 06520.
Minsoo KhangDepartment of Biomedical Engineering, Yale University, New Haven, CT 06520.
Dagan HadarAvram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Alice GaudinDepartment of Biomedical Engineering, Yale University, New Haven, CT 06520.
Fan YangDepartment of Biomedical Engineering, Yale University, New Haven, CT 06520.
Ewa Folta-StogniewW. M. Keck Biotechnology Research Laboratory, Yale University School of Medicine, New Haven, CT 06511.
W Mark SaltzmanDepartment of Biomedical Engineering, Yale University, New Haven, CT 06520.ORCID 0000-0002-2163-549X
Miriam AmiramAvram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel; mamiram@bgu.ac.il farren.isaacs@yale.edu.
Farren J IsaacsDepartment of Molecular, Cellular & Developmental Biology, Yale University, New Haven, CT 06520; mamiram@bgu.ac.il farren.isaacs@yale.edu.ORCID 0000-0001-8615-8236
Yale University · USBen-Gurion University of the Negev · ILW. M. Keck Foundation · US

Funding

Revealing substrates and phosphoproteome level function of human STE20 kinasesR01GM117230 · NIGMS · YALE UNIVERSITY · PI ISAACS, FARREN J., RINEHART, JESSE · 2015 to 2024
$3.2M
Biacore T100 SPR system for studying and characterizing biomolecular interactionS10RR026992 · NCRR · YALE UNIVERSITY · PI FOLTA-STOGNIEW, EWA JOANNA · 2009 to 2009
$364k
Production and application of recombinant biopolymers with exotic chemistriesK99EB019501 · NIBIB · YALE UNIVERSITY · PI AMIRAM, MIRIAM · 2016 to 2016
$50k
NCRR NIH HHS S10 RR026992NIBIB NIH HHS K99 EB019501NIGMS NIH HHS R01 GM117230
6 · The paper itself

Abstract

The use of biologics in the treatment of numerous diseases has increased steadily over the past decade due to their high specificities, low toxicity, and limited side effects. Despite this success, peptide- and protein-based drugs are limited by short half-lives and immunogenicity. To address these challenges, we use a genomically recoded organism to produce genetically encoded elastin-like polypeptide-protein fusions containing multiple instances of

Indexed as

Amino AcidsAnimalsBiopolymersHalf-LifeLipidsMicePeptidesProtein EngineeringProteinsSynthetic BiologyAmino AcidsBiopolymersLipidsPeptidesProteinsgenome recodingnoncanonical amino acidsprotein engineeringserum protein half-life extensionsynthetic biology

Identifiers

PMID35046019
PMCPMC8794819
OpenAlexW4205499673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.